Table II.
Proposed minimal clinical dataset for the treatment of PRP using biologic agents including all reported cases of treatment with secukinumab (including the 3 reported cases)
| Case | Reference | Patient age at onset | Patient gender | Time since disease onset | Griffiths subtype of PRP | Medical comorbidities | FHx Pso | FHx PRP | Baseline quality of life assessment |
Clinical endpoints |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment history |
Percentage of body surface area improvement |
PASI |
Time to response |
AE |
||||||||||||
| Prior treatment | Prior response | AE | NR | 100 | NR | 2 wk | NR | |||||||||
| 1 | Kevric8 | 54 | F | 52 y | V | NR | NR | NR | MTX Isotretinoin Acitretin Infliximab Adalimumab |
Limited Limited Limited Limited Limited |
NR | NR | 100 | NR | 2 wk | NR |
| 2 | Gauci et al9 | 33 | F | 9 y | II | Vesicoureteral reflux, hydronephrosis | No | No | Acitretin Cyclosporin MTX Infliximab Ustekinumab IVIG Omalizumab Prednisolone |
Minimal Partial Minimal Minimal Minimal Minimal Minimal Good |
NR | NR | NR | 27.6-5.6 | 4 wk | Oral & esophageal candidiasis |
| 3 | Schuster et al10 | 67 | M | Acute | I | NR | No | No | Acitretin | Minimal | NR | NR | 100 | NR | 8 wk | NR |
| 4 | Mariasy et al11 | 68 | M | Several wk | I | NR | NR | NR | MTX Acitretin Apremilast NBUVB |
Minimal Minimal Good Minimal |
NR | NR | 100 | NR | 6 mo | NR |
| 5 | Patient A | 52 | M | 4 wk | I | T1DM | No | No | Nil | NA | NA | 24/30 | 100 | NR | 14 wk | Nil |
| 6 | Patient B | 71 | M | 4 y | I (Paraneoplastic) |
CLL | No | No | MTX Acitretin Cyclosporin NBUVB |
Minimal Minimal Minimal Minimal |
28/30 | 20 | NR | NA | Nil | |
| 7 | Patient C | 61 | M | 30 y | II | Nil | Yes | No | MTX Acitretin NBUVB |
Minimal Minimal Minimal |
20/30 | 11 | NR | NA | Worsening | |
AE, Adverse events; FHx, family history; MTX, methotrexate; NA, not applicable; NBUVB, narrowband ultraviolet B; NR, not reported; pso, psoriasis; T1DM, type 1 diabetes mellitus.